An international helium exploration company is expanding its findings in northeastern Minnesota. Pulsar Helium Inc., said its Jetstream #5 appraisal well has recorded the highest bottom-hole pressure ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
The Denver Police Department is crediting a new drone program with helping reduce wait times and making its response to emergency calls more effective. The pilot program using Drone as First Responder ...
NASHVILLE, Tenn. (WZTV) — Air travelers should expect worsening cancellations and delays this week, even if the government shutdown ends, as the Federal Aviation Administration continues deeper cuts ...
Department of Analytical Chemistry, Faculty of Chemistry, K.N. Toosi University of Technology, P.O. Box 16315-1618, Postal Code 15418-49611 Tehran, Iran Nanomaterial, Separation and Trace Analysis ...
Google confirmed the 100 million milestone exclusively to CNET. Here's what's coming next for Flow and its AI-assisted creators. Katelyn is a writer with CNET covering artificial intelligence, ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio ...
Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
Century Head Start center on Hecker Road shutting its doors on July 18 Declining enrollment, teacher shortage, funding cuts play role in the consolidation of the centers Forty-one Century Head Start ...
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results